--- page 1 ---
1
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange ”)
and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents of this
announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those
defined in the prospectus dated December 30, 2024 (the “Prospectus ”) issued by BrainAurora Medical Technology
Limited ( 腦動極光醫療科技有限公司 ) (the “Company ”).
This announcement is for information purposes only and does not constitute an offer or an invitation to induce an
offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a
prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global
Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in
relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.
This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale
of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is
not for release, publication or distribution, directly or indirectly, in or into the United States or any other jurisdiction
where such distribution is prohibited by law, nor is this announcement an offer for sale or solicitation to purchase or
subscribe for securities in the United States or any other jurisdictions.
The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended
from time to time (the “U.S. Securities Act ”), or any applicable state securities laws and may not be offered, sold,
pledged or transferred within the United States or to, or for the account or benefit of, U.S. persons (as defined in
Regulation S under the U.S. Securities Act (the “Regulation S ”), except pursuant to an exemption from, or in a
transaction not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered
and sold outside the United States in offshore transactions in reliance on Regulation S. There will be no public offer of
securities in the United States.
In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited, as the
stabilizing manager (the “Stabilizing Manager ”), or any person acting for it, on behalf of the Underwriters, may over-
allocate or effect short sales or any other stabilizing transactions with a view to stabilizing or maintaining the market
price of the Offer Shares at a level higher than that which might otherwise prevail in the open market. However,
there is no obligation on the Stabilizing Manager or any person acting for it to conduct any such stabilizing action.
Such stabilizing activity, if commenced, will be done at the absolute discretion of the Stabilizing Manager and may
be discontinued at any time. Such stabilization action, if commenced, may be effected in all jurisdictions where it is
permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including
the Securities and Futures (Price Stabilising) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made
under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).
Potential investors should be aware that stabilizing action by the Stabilizing Manager, or any person acting for it,
is not permitted to support the price of the Shares for longer than the stabilizing period, which begins on the day on
which trading of the Shares commences on the Hong Kong Stock Exchange and ends on the 30th day after the last
day for the lodging of applications under the Hong Kong Public Offering. The stabilizing period is expected to end
on Sunday, February 2, 2025. As a result, demand for the Shares, and their market price, may fall after the end of the
stabilizing period.
Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of
the Hong Kong Underwriters) shall in their sole discretion be entitled to terminate the Hong Kong Underwriting
Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting –
Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination ” in the Prospectus at any time
prior to 8:00 a.m. (Hong Kong time) on the Listing Date.


--- page 2 ---
2
BrainAurora Medical Technology Limited
腦動極光醫療科技有限公司
(Incorporated in the Cayman Islands with limited liability)
GLOBAL OFFERING
Number of Offer Shares under the
Global Offering
: 181,112,000 Shares
Number of Hong Kong Offer Shares : 18,112,000 Shares
Number of International Offer Shares : 163,000,000 Shares
Offer Price : HK$3.22 per Offer Share, plus
brokerage of 1%, SFC transaction levy
of 0.0027%, Stock Exchange trading
fee of 0.00565% and AFRC
transaction levy of 0.00015% (payable
in full on application in Hong Kong
dollars and subject to refund)
Nominal value : US$0.0000001 per Share
Stock code : 6681
Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
Joint Bookrunners and Joint Lead Managers
Joint Bookrunners and Joint Lead Managers


--- page 3 ---
3
BrainAurora Medical Technology Limited (脑动极光医疗科技有限公司)
ANNOUNCEMENT OF ALLOTMENT RESULTS
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same
meanings as those defined in the prospectus dated December 30, 2024 (the “Prospectus”) issued by
BrainAurora Medical Technology Limited (脑动极光医疗科技有限公司) (the “Company”).
Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders
and prospective investors should be aware that the price of the Shares could move substantially even with a
small number of Shares traded and should exercise extreme caution when  dealing in the Shares.
SUMMARY
*See note at the end of the announcement
Over-allocation
No. of Offer Shares over-allocated 0
The Overall Coordinators confirmed that there has been no over-allocation of the Offer Shares in the International
Offering. Therefore, it is expected that the Over -allotment Option will not be exercised and the stock borrowing
agreement will not be entered into for the purpose of covering over-allocations in the International Offering.
Gross proceeds refers to the amount to which the Company is entitled to receive. For details of the use of proceeds,
please refer to the section headed “Future Plans and Use of Proceeds” in the Prospectus.
Company information
Stock code 6681
Stock short name BRAINAURORA-B
Dealings commencement date January 8, 2025*
Price Information
Final Offer Price HK$3.22
Offer Price Adjustment exercised N/A
Offer Shares and Share Capital
Number of Offer Shares 181,112,000
Number of Offer Shares in Hong Kong Public Offering 18,112,000
Number of Offer Shares in the International Offering 163,000,000
Number of issued Shares upon Listing 1,266,278,000
Proceeds
Gross proceeds (Note) HK$583.18 million
Less: Estimated listing expenses payable based on final Offer Price HK$(81.86) million
Net proceeds HK$501.32 million


--- page 4 ---
4
ALLOTMENT RESULTS DETAILS
HONG KONG PUBLIC OFFERING

No. of valid applications 10,891
No. of successful applications 7,468
Subscription level 11.39 times
Claw-back triggered No
No. of Offer Shares initially available under the Hong Kong Public
Offering 18,112,000
Final no. of Offer Shares under the Hong Kong Public Offering 18,112,000
% of final no. of Offer Shares under the Hong Kong Public Offering to
the Global Offering 10.00%

For details of the final allocation of shares to the Hong  Kong Public Offering, investors can refer to
www.hkeipo.hk/iporesult to perform a search by name or identification number or www.hkeipo.hk/iporesult for
the full list of allottees.
INTERNATIONAL OFFERING

No. of placees 114
Subscription Level 1.01 times
No. of Offer Shares initially available under the International Offering 163,000,000
Final no. of Offer Shares under the International Offering 163,000,000
% of final no. of Offer Shares under the International Offering to the
Global Offering 90.00%

The Directors confirm that, to the best of their knowledge, information and belief, save for a waiver from strict
compliance with Rule 10.04 of and consent under paragraph 5(2) of Appendix F1 to the Listing Rules in respect of
subscriptions of the Offer Shares by Mr. Huang Guangwei, an existing Shareholder, as cornerstone investor, (i)
none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the
Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial
Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates;
and (ii) none of the placees and the public who have pu rchased the Offer Shares are accustomed to taking
instructions from the Company, any of the Directors, chief executive of the Company, Controlling Shareholders,
substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close
associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name
or otherwise held by him/her/it.


--- page 5 ---
5
The placees in the International Offering include the following:
Cornerstone Investors
Investor
No. of Offer
Shares allocated
% of Offer
Shares(Note1)
% of total issued share
capital after the Global
Offering(Note1)
Existing shareholders or
their close associates
Tasly (Hong Kong)
Pharmaceutical Investment
Limited (天士力（香港）
醫藥投資有限公司)
12,074,000 6.67% 0.95% No
Tasly (International)
Healthcare Investment &
Development Company
Limited (天士力(國際)醫
療健康投資發展有限公
司)
24,148,000 13.33% 1.91% No
Suzhou Ceyuan Fuhai
Enterprise Management
Partnership (Limited
Partnership) (蘇州策源扶
海企業管理合夥企業
（有限合夥）)
70,525,000 38.94% 5.57% No
Huang Guangwei (黃光
偉) 9,659,000 5.33% 0.76% Yes
Subtotal 116,406,000 64.27% 9.19%


--- page 6 ---
6
Allottee with waiver/consent obtained
Investor
No. of Offer
Shares allocated
% of Offer
Shares(Note1)
% of total issued
share capital after
the Global
Offering(Note1) Relationship
Allotee with waiver from strict compliance with Rule 10.04 of and consent under paragraph 5(2) of Appendix
F1 to the Listing Rules in respect of subscriptions of Offer Shares by an existing Shareholder as Cornerstone
Investor(Note2)
Huang Guangwei (黃光
偉) 9,659,000 5.33% 0.76%
A Cornerstone Investor
and an existing
Shareholder
Subtotal 9,659,000 5.33% 0.76%
Notes:
1. The Over-allotment Option has not been exercised and will not be exercised.
2. Mr. Huang Guangwei (黃光偉) is a Cornerstone Investor and an existing Shareholder. The Stock Exchange has granted a waiver from
strict compliance with Rule 10.04 of and consent under paragraph 5(2) of Appendix F1 to the Listing Rules in respect of subsc riptions
of Offer Shares by an existing Shareholder as Cornerstone Investor. For details, see the section headed “Waivers – Waiver from strict
compliance with Rule 10.04 of and consent under paragraph 5(2) of Appendix F1 to the Listing Rules in respect of subscriptions of Offer
Shares by an existing Shareholder as Cornerstone Investor” in the Prospectus and the section headed “Others / Additional Information
– Placing to an existing shareholder as cornerstone investor with a waiver from the strict compliance with Rule 10.04 of the Li sting
Rules and a prior consent under paragraph 5(2) of Appendix F1 to the Listing Rules” in this announcement.
LOCK-UP UNDERTAKINGS
Controlling Shareholders
Name
Number of Shares held in the
Company subject to lock-up
undertakings upon Listing
% of shareholding in the
Company subject to lock-up
undertakings upon Listing
Last day subject to the lock-
up undertakings(Note 1)
ZTan Limited  275,468,000 21.75% January 7, 2026
Wispirits Limited  109,052,000 8.61% January 7, 2026
Wiseforward Limited  44,503,000 3.51% January 7, 2026
Neurobright Limited  30,400,000 2.40% January 7, 2026
Subtotal 459,423,000 36.28%
Note:
1. The Controlling Shareholders will cease to be prohibited from disposing of or transferring Shares after the indicated date.  Apart from
the lock-up requirements under Rule 10.07 of the Listing Rules, the Controlling Shareholders has undertaken to the Joint Sponsors, the
Overall Coordinators and the Company that, save for certain special circumstances, they will not, and will procure that no company or
legal entity controlled by them or any nominee or trustee holding in trust for them will,  at any time during the period ending on, and
including, the date falling twelve months after the Listing Date, dispose of, nor enter into any agreement to dispose of or otherwise create
any options, rights, interests or encumbrances in respect of, any of the Shares held by it on the date of the Prospectus.  For details, see
the section headed “History, Reorganization and Corporate Structure - Lock-Up Arrangements” and “Underwriting - Underwriting
Arrangements - Hong Kong Public Offering - Undertakings by the Controlling Shareholders” in the Prospectus.


--- page 7 ---
7
Existing Shareholders
Name
Number of shares held in
the Company subject to lock-
up undertakings upon
Listing
% of shareholding in the
Company subject to lock-up
undertakings upon Listing
Last day subject to the lock-
up undertakings(Note 1)
Northern Light Strategic
Fund IV L.P.  9,514,000 0.75% January 7, 2026
Northern Light Venture
Fund IV L.P. 115,729,000 9.14% January 7, 2026
Northern Light Partners
Fund IV L.P.  1,611,000 0.13% January 7, 2026
Crusky Limited  123,527,000 9.76% January 7, 2026
Healthblooming Limited  99,104,000 7.83% January 7, 2026
Wisdomspirit Holding
Limited  85,166,000 6.73% January 7, 2026
China Frontier Capital
Holding Limited (中國方
大資本控股有限公司)
 70,143,000 5.54% January 7, 2026
Integriness Limited  40,327,000 3.18% January 7, 2026
CICC Healthcare
Investment Fund, L.P.  19,444,000 1.54% January 7, 2026
Beijing Pegasus Travel
Star Enterprise
Management Center
(Limited Partnership) (北
京飛馬旅之星企業管理
中心(有限合夥))
 17,209,000 1.36% January 7, 2026
Shenzhen Fengrui
Dingxing Equity
Investment Fund
Partnership (Limited
Partnership) (深圳灃瑞鼎
興股權投資基金合夥企
業(有限合夥))
 14,144,000 1.12% January 7, 2026
Anji Shundian Limited  11,150,000 0.88% January 7, 2026
Ambertech Limited  7,502,000 0.59% January 7, 2026
Huang Guangwei (黃光
偉) 7,502,000 0.59% January 7, 2026


--- page 8 ---
8
Jenny Wang Limited  3,671,000 0.29% January 7, 2026
Subtotal 625,743,000 49.42%
Note:
1. Each of the existing Shareholders of the Company will cease to be prohibited from disposing of or transferring Shares after the indicated
date. Each of the existing Shareholders has entered into a deed of lock-up undertaking in favor of the Joint Sponsors, the Overall
Coordinators and the Company imposing certain restrictions on dealings with their respective Shares. Pursuant to the deed of lock-up
undertaking, save for certain special circumstances, each of the existing Shareholders undertakes that, inter alia, it/he will not, and will
procure that no company or legal entity controlled by it/him or any nominee or trustee holding in trust for it/him will, at any time during
the period ending on, and including, the date falling twelve months after the Listing Date , dispose of, nor enter into any agreement to
dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the Shares held by it/him  on the date
of the Prospectus . For details, see the section headed “ Underwriting - Underwriting Arrangements - Hong Kong Public Offering -
Undertakings by existing Shareholders” in the Prospectus.
Cornerstone Investors
Name
Number of shares held
in the Company subject
to lock-up undertakings
upon Listing
% of shareholding in the
Company subject to lock-up
undertakings upon Listing
Last day subject to the lock-
up undertakings (Note 1)
Tasly (Hong Kong)
Pharmaceutical Investment
Limited (天士力（香港）
醫藥投資有限公司)
12,074,000 0.95% July 7, 2025
Tasly (International)
Healthcare
Investment&Development
Company Limited (天士力
(國際)醫療健康投資發展
有限公司)
24,148,000 1.91% July 7, 2025
Suzhou Ceyuan Fuhai
Enterprise Management
Partnership (Limited
Partnership) (蘇州策源扶海
企業管理合夥企業（有限
合夥）)
70,525,000   5.57% July 7, 2025
Huang Guangwei (黃光偉)
(Note 2) 9,659,000 0.76% July 7, 2025
Subtotal 116,406,000   9.19%
Notes:
1. In accordance with the respective Cornerstone Investment Agreement, the required lock -up ends on July 7, 2025. The Cornerstone
Investors will cease to be prohibited from disposing of or transferring the Shares subscribed for pursuant to their respective Cornerstone
Investment Agreement after the indicated date.


--- page 9 ---
9
2. Mr. Huang Guangwei (黃光偉) is an existing Shareholder of the Company. For further details, see the section headed “Waivers – Waiver
from strict compliance with Rule 10.04 of and consent under paragraph 5(2) of Appendix F1 to the Listing Rules in respect of subscriptions
of Offer Shares by an existing Shareholder as Cornerstone Investor ” in the Prospectus and the section headed “Others / Additional
Information – Placing to an existing shareholder as cornerstone investor with a waiver from the strict compliance with Rule 10.04 of the
Listing Rules and a prior consent under paragraph 5(2) of Appendix F1 to the Listing Rules” in this announcement. Shares subscribed by
Mr. Huang Guangwei (黃光偉) as a cornerstone investor are subject to lock-up undertaking as indicated above.


--- page 10 ---
10
PLACEE CONCENTRATION ANALYSIS
Placees*
Number of Shares
allocated
Allocation as % of
International Offering
Allocation as % of total
Offer Shares
Number of
Shares held upon Listing
% of total issued share
capital upon Listing
Top 1 70,525,000 43.27% 38.94% 70,525,000 5.57%
Top 5 151,226,000 92.78% 83.50% 158,728,000 12.54%
Top 10 162,777,000 99.86% 89.88% 170,279,000 13.45%
Top 25 162,911,000 99.95% 89.95% 170,413,000 13.46%
Note:
* Ranking of placees is based on the number of Shares allotted to the placees.
SHAREHOLDERS CONCENTRATION ANALYSIS
Shareholders*
Number of Shares
allocated
Allotment as % of
International Offering
Allotment as % of total
Offer Shares
Number of Shares held
upon Listing
% of total issued Shares
capital upon Listing
Top 1 0 0.00% 0.00% 558,527,000 44.11%
Top 5 70,525,000 43.27% 38.94% 964,599,000 76.18%
Top 10 134,517,000 82.53% 74.27% 1,158,505,000 91.49%
Top 25 167,310,000 102.64%# 92.38% 1,252,476,000 98.91%
Notes:
* Ranking of Shareholders is based on the number of Shares held by the Shareholders upon Listing.
#  More than 100% as some Shareholders are allotted with Shares through the Hong Kong Public Offering.


--- page 11 ---
11
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
Subject to the satisfaction of the conditions set out in the Prospectus, 10,891 valid applications made by the
public will be conditionally allocated on the basis set out below:
NO. OF
SHARES
APPLIED FOR
NO. OF VALID
APPLICATIONS
BASIS OF
ALLOTMENT
/ BALLOT
APPROXIMATE
PERCENTAGE
ALLOTTED OF THE
TOTAL NO. OF
SHARES APPLIED FOR
Pool A
1,000 5,285 2,643 out of 5,285 applicants to receive
1,000 Shares
50.01%
2,000 783 470 out of 783 applicants to receive
1,000 Shares
30.01%
3,000 1,153 813 out of 1,153 applicants to receive
1,000 Shares
23.50%
4,000 238 186 out of 238 applicants to receive
1,000 Shares
19.54%
5,000 372 313 out of 372 applicants to receive
1,000 Shares
16.83%
6,000 137 124 out of 137 applicants to receive
1,000 Shares
15.09%
7,000 62 59 out of 62 applicants to receive 1,000
Shares
13.59%
8,000 78 77 out of 78 applicants to receive 1,000
Shares
12.34%
9,000 46 1,000 Shares  11.11%
10,000 428 1,000 Shares plus 22 out of 428
applicants to receive an additional 1,000
Shares
10.51%
15,000 776 1,000 Shares plus 159 out of 776
applicants to receive an additional 1,000
Shares
8.03%
20,000 162 1,000 Shares plus 53 out of 162
applicants to receive an additional 1,000
Shares
6.64%
25,000 69 1,000 Shares plus 30 out of 69 applicants
to receive an additional 1,000 Shares
5.74%
30,000 398 1,000 Shares plus 202 out of 398
applicants to receive an additional 1,000
Shares
5.03%
35,000 69 1,000 Shares plus 41 out of 69 applicants
to receive an additional 1,000 Shares
4.55%
40,000 59 1,000 Shares plus 39 out of 59 applicants
to receive an additional 1,000 Shares
4.15%
45,000 26 1,000 Shares plus 19 out of 26 applicants
to receive an additional 1,000 Shares
3.85%
50,000 134 1,000 Shares plus 105 out of 134
applicants to receive an additional 1,000
Shares
3.57%


--- page 12 ---
12
60,000 74 1,000 Shares plus 66 out of 74 applicants
to receive an additional 1,000 Shares
3.15%
70,000 37 2,000 Shares 2.86%
80,000 49 2,000 Shares plus 4 out of 49 applicants
to receive an additional 1,000 Shares
2.60%
90,000 45 2,000 Shares plus 9 out of 45 applicants
to receive an additional 1,000 Shares
2.44%
100,000 239 2,000 Shares plus 84 out of 239
applicants to receive an additional 1,000
Shares
2.35%
200,000 68 2,000 Shares plus 54 out of 68 applicants
to receive an additional 1,000 Shares
1.40%
300,000 22 3,000 Shares 1.00%
400,000 15 3,000 Shares plus 9 out of 15 applicants
to receive an additional 1,000 Shares
0.90%
500,000 11 3,000 Shares plus 9 out of 11 applicants
to receive an additional 1,000 Shares
0.76%
600,000 6 4,000 Shares 0.67%
700,000 3 4,000 Shares plus 1 out of 3 applicants to
receive an additional 1,000 Shares
0.62%
800,000 4 4,000 Shares plus 2 out of 4 applicants to
receive an additional 1,000 Shares
0.56%
1,000,000 30 5,000 Shares 0.50%
Total 10,878 Total number of Pool A successful
applicants: 7,455
Pool B
 2,000,000  8 504,000 Shares 25.20%
 3,000,000  4 755,000 Shares 25.17%
 8,000,000  1 2,004,000 Shares 25.05%
Total 13 Total number of Pool B successful
applicants: 13
As of the date of this announcement, the relevant subscription monies previously deposited in the designated
nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors  should
contact their relevant brokers for any inquiries.
COMPLIANCE WITH LISTING RULES AND GUIDANCE
The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which
consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation
to the placing, allotment and listing of the Company’s shares.
The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public
(as the case may be) directly or indirectly  for each Offer Share subscribed for or purchased by them was  the
same as the final Offer Price  in addition to any brokerage, AFRC transaction levy, SFC transaction levy and
Stock Exchange trading fee payable.


--- page 13 ---
13
OTHERS / ADDITIONAL INFORMATION
Placing to an existing shareholder as cornerstone investor with a waiver from the strict compliance with
Rule 10.04 of the Listing Rules and a prior consent under paragraph 5(2) of Appendix F1 to the Listing
Rules
Our Company has applied to the Stock Exchange, and the Stock Exchange has granted, a waiver from the strict
compliance with Rule 10.04 of the Listing Rules and a consent under paragraph 5(2) of Appendix F1 to the
Listing Rules to permit our Company to allo w Mr. Huang Guangwei (黃光偉), an existing shareholder, to
participate in the Global Offering as a cornerstone investor. The allocation of Offer Shares to Mr. Huang
Guangwei (黃光偉) is in compliance with all the conditions under the waiver/consent granted by th e Stock
Exchange. For further details of the allocations of Offer Shares to Mr. Huang Guangwei (黃光偉 ) as a
cornerstone investor, see the section headed “Allotment Results Details – International Offering – Allottee with
waiver/consent obtained” in this announcement.
DISCLAIMERS
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and  Hong Kong
Securities Clearing Company Limited take no responsibility for the contents of this announcement, make
no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any
loss howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in or into  the United
States (including its territories and possessions, any state of the United States and the District of
Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or
subscribe for securities in the United States. The securities mentioned herein have not been, and will not be,
registered under the United States Securities Act of 1933,  as amended (the “ U.S. Securities Act ”). The
securities may not be offered or sold in the United States except pursuant to an exemption from the registration
requirements of the U.S. Securities Act  and in compliance with any applicable state securities laws, or
outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be
no public offer of securities in the United States.
The Offer Shares are being offered and sold outside the United States in offshore transactions in  reliance on
Regulation S under the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an invitation or offer to
acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential  investors
should read the Prospectus for detailed information about the Global Offering described below before
deciding whether or not to invest in the Shares thereby being offered.
* Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on
behalf of the Hong Kong Underwriters) shall in their sole discretion be entitled to terminate the Hong Kong
Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section
headed “Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for
Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which
is currently expected to be on January 8, 2025).


--- page 14 ---
14
PUBLIC FLOAT
Immediately following the completion of the Global Offering, an aggregate of 372,204,000 Shares
or approximately 29.39% of the total issued share capital of the Company will be held in the
public hands. Therefore, the number of Shares in the public hands represents no less than 25% of
the total issued share capital of the Company, satisfying the minimum percentage requirement in
compliance with Rule 8.08(1) of the Listing Rules.
The Directors confirm that, immediately following the completion of the Global Offering, (i)
no placee will, individually, be placed more than 10% of the enlarged issued share capital of
the Company immediately after the Global Offering; (ii) there will not be any new substantial
Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders
do not hold more than 50% of the Shares held in the public hands at the time of the Listing in
compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300
Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.
COMMENCEMENT OF DEALINGS
The Share certificates will only become valid evidence of title at 8:00 a.m. on Wednesday,
January 8, 2025 (Hong Kong time), provided that the Global Offering has become unconditional
and the right of termination described in the paragraph headed “Underwriting – Underwriting
Arrangements – Hong Kong Public Offering – Grounds for Termination ” in the Prospectus has not
been exercised. Investors who trade the Shares on the basis of publicly available allocation details
prior to the receipt of Share certificates or prior to the Share certificates becoming valid evidence
of title do so entirely at their own risk.
Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Wednesday,
January 8, 2025 (Hong Kong time), it is expected that dealings in the Shares on the Stock
Exchange will commence at 9:00 a.m. on Wednesday, January 8, 2025 (Hong Kong time).
The Shares will be traded in board lots of 1,000 Shares each, and the stock code of the Shares will
be 6681.
By order of the Board
BrainAurora Medical Technology Limited
Mr. Tan Zheng
Chairman and Executive Director
Hong Kong, January 7, 2025
As of the date of this announcement, the board of directors of the Company comprise: (i) Mr. Tan
Zheng and Dr. Wang Xiaoyi as executive directors; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng
Feng as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Li Yuezhong as
proposed independent non-executive directors.
